Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP2C19 | P33261 | 1/20 | 0.36 |
| ▸ | USP2 | O75604 | 1/20 | 0.31 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.31 |
| ▸ | LMNA | P02545 | 1/20 | 0.31 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.31 |
| ▸ | TSHR | P16473 | 1/20 | 0.31 |
| ▸ | BLM | P54132 | 1/20 | 0.31 |
| ▸ | CACNA2D1 | P54289 | 1/20 | 0.31 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31087757 | 0.92 | CYP2C19 (0.30) | CYP2C19 | |
| SCHEMBL7344994 | 0.79 | CYP2C19 (0.32) | CYP2C19 | |
| SCHEMBL29973085 | 0.73 | CYP2C19 (0.42) | CYP2C19USP2ALDH1A1LMNACYP1A2 | |
| SCHEMBL3934353 | 0.72 | ARG1 (0.34) | CYP2C19 | |
| SCHEMBL28643393 | 0.71 | CYP2C19 (0.32) | CYP2C19 | |
| SCHEMBL8371988 | 0.69 | FFAR3 (0.31) | — | |
| SCHEMBL8993303 | 0.69 | FFAR3 (0.31) | — | |
| Acetic Acid SCHEMBL1528008 | 0.66 | FFAR3 (0.39) | — | |
| Acetic Acid SCHEMBL3991283 | 0.66 | FFAR3 (0.39) | — | |
| Acetic Acid SCHEMBL1566799 | 0.66 | FFAR3 (0.39) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240327458-A1 | MACROCYCLIC PEPTIDOMIMETIC PROTEASE INHIBITOR AND USE THEREOF | TENCENT TECHNOLOGY (SHENZHEN) COMPANY LIMITED (CN) | 2024-10-03 | — | — | US | disclosed |
| EP-4406962-A1 | MACROCYCLIC PEPTIDOMIMETIC PROTEASE INHIBITOR AND USE THEREOF | Tencent Technology (Shenzhen) Company Limited (CN) | 2024-07-31 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240327458-A1 | MACROCYCLIC PEPTIDOMIMETIC PROTEASE INHIBITOR AND USE THEREOF | ACE, FURIN, ACE2 | CYP2C19 266/4885USP2 826/4885ALDH1A1 4138/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.